The injection has been developed by Helsinn and Glenmark has exclusive marketing rights for this product in India.
Buy / Sell Glenmark share
Recommended ArticlesView All
Budget 2023: Aiming to establish India as skill capital of the world
Feb 3, 2023 IST5 Min(s) Read
Budget 2023: New Income Tax slab — A tectonic shift indeed in favour of the middle class
Feb 3, 2023 IST4 Min(s) Read
Budget 2023: Taking a bold step to unlock India’s potential
Feb 2, 2023 IST2 Min(s) Read
Budget 2023: Moving closer towards universal health through proper implementation is key
Feb 2, 2023 IST3 Min(s) Read
Akynzeo is a fixed-dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg) and is available as a ready-to-dilute intravenous (IV) injection.
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent both acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV).
The injection has been developed by Helsinn and Glenmark has exclusive marketing rights for this product in India. The drug is already being marketed in the European Union, the United States, and Australia.
As per the latest National Cancer Registry Programme data, cancer cases in the country are projected to rise by 12.8 percent by 2025 from 13.9 lakh cases in 2020.
Glenmark has a legacy of introducing new and effective prophylactic treatment options for CINV among cancer patients in India.
Around two decades ago, Glenmark launched Aprecap (Aprepitant Capsules), the first NK1 receptor blocker, and a few years later, introduced Aprecap I.V. injection. Subsequently in 2018, Glenmark revolutionized cancer-supportive care in the country by launching Akynzeo oral capsules.
Shares of Glenmark Pharma ended 0.38 percent higher at Rs 419.50 on Monday.